Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: A well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia

Cancer Research

Volumn 66, Issue 3, 2006, Pages 1664-1674

  Emmenegger, Urban ^a   Morton, Gerard C ^a   Francia, Giulio ^a   Shaked, Yuval ^a   Franco, Marcela ^a   Weinerman, Adina ^a   Man, Shan ^a   Kerbel, Robert S ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; TIRAPAZAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CONTROL; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; LOW DRUG DOSE; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; OXYGEN TENSION; OXYGENATION; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL HYPOXIA; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN; PROSTATIC NEOPLASMS; TRIAZINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 32944478170     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2598     Document Type: Article

References (58)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
2. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
3. Marx J. Cancer. Encouraging results for second-generation antiangiogenesis drugs. Science 2005;308:1248-9.
4. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36.
5. st Annual ASCO Meeting; Orlando, FL; 2005.
6. Browder T, Butterfield CE, Kraling BM, et al. Antiangjogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
7. Emmenegger U, Man S, Shaked Y, et al. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 2004;64:3994-4000.
8. Bocci G, Tuccori M, Emmenegger U, et al. Cyclophosphamide-methotrexate "metronomic" chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol 2005;16:1243-52.
9. Vanchieri C. When will the U.S. flinch at cancer drug prices? J Natl Cancer Inst 2005;97:624-6.
10. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anticancer therapeutic agents. BioEssays 1991;13:31-6.
11. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24.
12. Colleoni M, Rocca A. Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002;13:73-80.
13. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309.
14. Glade Bender J, Cooney EM, Kandel JJ, Yamashiro DJ. Vascular remodeling and clinical resistance to anti-angiogenic cancer therapy. Drug Resist Updat 2004;7:289-300.
15. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002;295:1526-8.
16. Kerbel RS, Yu J, Tran J, et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001;20:79-86.
17. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
18. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
19. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437-47.
20. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-76.
21. Blagosklonny MV. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy [review]. Int J Oncol 2001;19:257-62.
22. Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell 2004;5:13-7.
23. Kerbel RS, Viloria-Petit A, Klement G, Rak J. "Accidental" anti-angiogenic drugs. Anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 2000;36:1248-57.
24. Nagasawa H, Yamashita M, Mikamo N, et al. Design, synthesis and biological activities of antiangiogenic hypoxic cytotoxin, triazine-N-oxide derivatives. Comp Biochem Physiol A Mol Integr Physiol 2002;132:33-40.
25. Huxham LA, Kyle AH, Baker JHE, McNicol KL, Minchinton AI. Tirapazamine causes vascular dysfunction [abstract 3015]. 96th Annual AACR Meeting; Anaheim, CA; 2005.
26. 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997;3:177-82.
27. Durand RE, Olive PL. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat Oncol Investig 1997;5:213-9.
28. Cao Y, Li CY, Moeller BJ, et al. Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation. Cancer Res 2005;65:5498-505.
29. Cliffe S, Taylor ML, Rutland M, Baguley BC, Hill RP, Wilson WR. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys 1994;29:373-7.
30. Masunaga S, Ono K, Nishimura Y, et al. Combined effects of tirapazamine and mild hyperthermia on antiangiogenic agent (TNP-470) treated tumors-reference to the effect on intratumor quiescent cells. Int J Radiat Oncol Biol Phys 2000;47:799-807.
31. Man S, Bocci G, Francia G, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002;62:2731-5.
32. Parker C, Milosevic M, Toi A, et al. Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:750-7.
33. Bates ML, Feingold A, Gold MI. The effects of anesthetics on an in-vivo oxygen electrode. Am J Clin Pathol 1975;64:448-51.
34. Moeller BJ, Cao Y, Vujaskovic Z, Li CY, Haroon ZA, Dewhirst MW. The relationship between hypoxia and angiogenesis. Semin Radiat Oncol 2004;14:215-21.
35. Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett 2003;195:1-16.
36. Hodgkiss RJ. Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia. Anticancer Drugs 1998;13:687-702.
37. Kasan J, Shnyder SD, Bibby M, Double JA, Bicknel R, Jayson GC. Quantitative angiogenesis assays in vivo - a review. Angiogenesis 2004;7:1-16.
38. Shaked Y, Emmenegger U, Man S, et al. The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005;106:3058-61.
39. Nevaldine B, Longo JA, Hahn PJ. The scid defect results in much slower repair of DNA double-strand breaks but not high levels of residual breaks. Radiat Res 1997;147:535-40.
40. Secomb TW, Hsu R, Ong ET, Gross JF, Dewhirst MW. Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol 1995;34:313-6.
41. Hafner C, Reichle A, Vogt T. New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARγ agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy. Curr Cancer Drug Targets 2005;5:393-419.
42. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005;23:939-52.
43. Shaked Y, Emmenegger U, Francia G, et al. Low-dose metronomic combined with intermittent bolusdose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 2005;65:7045-51.
44. du Manoir JM, Francia G, Man S, et al. Strategies for delaying or treating in vivo acquired resistance to trastuzumab (Herceptin) in human breast cancer xenografts. Clin Cancer Res. In press 2006.
45. Curran WJ, Mosvas B, Hancock S, et al. Phase I trial of oral tirazone (tirapazamine, TPZ) shows good bioavailability and tolerance [abstract 802]. 34th Annual ASCO Meeting; Los Angeles, CA; 1998.
46. Kakeji Y, Maehara Y, Ikebe M, Teicher BA. Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-β levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma. Int J Radiat Oncol Biol Phys 1997;37:1115-23.
47. 13C magnetic resonance spectroscopy, Eppendorf electrode, and redox scanning. Cancer Res 2003;63;8813-20.
48. Stolting S, Klink T, Bela C, Engels C, Wagner T. Metronomic scheduling of trofosfamide chemotherapy in human NSCLC xenografts highly increases therapeutic efficacy compared to conventional scheduling by inhibition of angiogenesis. Int J Clin Pharmacol Ther 2004;42:652-3.
49. Huang J, Soffer SZ, Kim ES, et al. Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res 2004;2:36-42.
50. Powis G, Kirkpatrick L, Hypoxia inducible factor-1α as a cancer drug target. Mol Cancer Ther 2004;3:647-54.
51. Weitman S, Mangold G, Marty J, et al. Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft. Cancer Chemother Pharmacol 1999;43:402-8.
52. Masunaga S, Ono K, Hori H, et al. Change in oxygenation status in intratumour total and quiescent cells following γ-ray irradiation, tirapazamine administration, cisplatin injection and bleomycin treatment. Br J Radiol 2000;73:978-86.
53. Hicks KO, Pruijn FB, Sturman JR, Denny WA, Wilson WR. Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. Cancer Res 2003;63:5970-7.
54. Denny WA. Prospects for hypoxia-activated anticancer drugs. Curr Med Chem Anti-Canc Agents 2004;4:395-9.
55. Koch CJ. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res 1993;53:3992-7.
56. Blumenthal RD, Taylor A, Osorio L, et al. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia. Int J Cancer 2001;94:564-71.
57. 18F-misonidazole (FMISO) PET-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with and without tirapazamine. Eur J Cancer Suppl 2004;2:149.
58. Evans SM, Judy KD, Dunphy I, et al. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res 2004;64:1886-92.